| > Dr May Faraj |
Contact info
Dr May Faraj
Clinical Research Institute of Montreal (IRCM)
110, Pins Avenue West - Office 1770.2
Montréal, QC H2W 1R7
Tel: 1-514-987-5655
Fax: 1-514-987-5645
E-mail: may.faraj@umontreal.ca
Research keywords
- Human nutrition
- Lipoproteins
- Adipose tissue
- Inflammation
- Insulin secretion
- Insulin sensitivity
- Metabolic disease
- Type 2 diabetes
- Obesity
- Stable isotopes
- Post-menopausal women
|
|
May Faraj, PDt, PhD
Junior Scientist, Department of Nutrition
Biographical Sketch
May Faraj obtained her MSc in Nutrition and her PhD in Experimental
medicine from McGill University in Montreal under the supervision of Dr Katherine
Cianflone. Her graduate work investigated the regulation of lipoprotein lipase activity,
lipoprotein metabolism and fatty acid trapping in adipose tissue using cell, mice and
human models. In 2004, she joined the lab of Dr Remi Rabasa-Lhoret, Department of
Nutrition, University of Montreal, as a CIHR-postdoctoral fellow exploring insulin
action and sensitivity in human. In 2007 she obtained CIHR New Investigator Award and
an academic position as junior scientist in the Department of Nutrition, University
of Montreal. She then joined Clinical Research Institute of Montreal (IRCM) in 2008
as an invited scientist, where she started her lab funded by CIHR operating grant and
CFI leader's opportunity funds, and in collaboration with Dr Rabasa-Lhoret and IRCM
physicians. Her clinical and basic research explores a hypothesis she instigated in
2006 linking the number of apoB-lipoproteins to the promotion and prevention of type
2 diabetes in humans. She is a member of L'Ordre Professionnel des Diététistes du
Québec since 1999.
Click here for pdf CV
Click here for PubMed listing
Research Interests
Dr Faraj research focuses on investigating the mechanisms linking
the number of atherogenic or apoB-lipoproteins (measured as plasma apoB) to the
promotion of inflammation, ineffective fatty acid trapping in adipose tissue and
insulin resistance in obese subjects. Accordingly she investigates whether targeting
subjects with the hyperapoB phenotype (i.e. elevated plasma apoB) by hypocaloric-dietary
interventions may reduce the risk of type 2 diabetes maximally in obese subjects,
particularly in post-menopausal women. To investigate these hypotheses, she utilizes
complementary in vivo, ex vivo and in vitro techniques to
follow the metabolism of dietary fat (stable and radioactive isotopes studies), to
assess inflammation (immunohistochemistry and gene expression), to fractionate and
characterize lipoproteins (ultracentrifugation, FPLC, gel electrophoresis) and to
assess insulin secretion, sensitivity and action (Botnia clamp and insulin-induced
glucose/lipid cellular metabolism).
|